Tibotec Pharmaceuticals, Ireland
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Tibotec Pharmaceuticals, Ireland sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Tibotec Pharmaceuticals, Ireland: 16 sponsored US clinical trials, none currently recruiting.
Tibotec Pharmaceuticals, Ireland sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 16 completed. 7 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Human Immunodeficiency Virus - Type 1, with 1 trials.
Top-decile sponsor footprint
Tibotec Pharmaceuticals, Ireland ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
16 total, page 1 of 1
TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435
NCT01046058
A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment
NCT00980330
A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents
NCT00915655
A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment
NCT00882908
TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents
NCT00665847
TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
NCT00543725
TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
NCT00540449
A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)
NCT00524368
A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents
NCT00355524
An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).
NCT00359021
TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
NCT00254046
TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.
NCT00258557
A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
NCT00110305
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
NCT00110877
An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.
NCT00081588
TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients
NCT00071097
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
| Phase 3 | 7 |
Therapeutic Areas
How the Tibotec Pharmaceuticals, Ireland archive is shaped
16 indexed studies, none listed as recruiting (0% open); 16 completed (100%).
Phase mix: 7 late (III/IV) vs 9 early (I/II) (balanced across stages).
Top condition: Human Immunodeficiency Virus - Type 1 (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Tibotec Pharmaceuticals, Ireland: archived-pipeline peers nationwide
Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Tibotec Pharmaceuticals, Ireland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 archived trials
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Tibotec Pharmaceuticals, Ireland page
16 registered trials is a research-attention snapshot, not an endorsement of Tibotec Pharmaceuticals, Ireland or any single study.
- None of Tibotec Pharmaceuticals, Ireland's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Human Immunodeficiency Virus - Type 1 is the condition Tibotec Pharmaceuticals, Ireland studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Human Immunodeficiency Virus - Type 1 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Tibotec Pharmaceuticals, Ireland pipeline card: 16 registered trials from official public datasets.Report a data error.